1. Home
  2. JFU vs ATNM Comparison

JFU vs ATNM Comparison

Compare JFU & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo 9F Inc.

JFU

9F Inc.

HOLD

Current Price

$2.30

Market Cap

30.6M

Sector

Finance

ML Signal

HOLD

Logo Actinium Pharmaceuticals Inc. (Delaware)

ATNM

Actinium Pharmaceuticals Inc. (Delaware)

HOLD

Current Price

$0.89

Market Cap

31.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JFU
ATNM
Founded
2006
2000
Country
China
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
30.6M
31.7M
IPO Year
2018
2013

Fundamental Metrics

Financial Performance
Metric
JFU
ATNM
Price
$2.30
$0.89
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$4.50
AVG Volume (30 Days)
2.1K
118.1K
Earning Date
12-09-2022
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
14.17
EPS
N/A
N/A
Revenue
N/A
$90,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$1.43
N/A
Revenue Growth
N/A
11.11
52 Week Low
$1.51
$0.88
52 Week High
$9.48
$1.89

Technical Indicators

Market Signals
Indicator
JFU
ATNM
Relative Strength Index (RSI) 34.43 36.09
Support Level N/A N/A
Resistance Level $2.88 $1.27
Average True Range (ATR) 0.11 0.05
MACD -0.00 -0.00
Stochastic Oscillator 0.00 6.94

Price Performance

Historical Comparison
JFU
ATNM

About JFU 9F Inc.

9F Inc is a digital technology and wealth management service provider aiming to empower institutional partners with financial technologies as well as attract investors with investment opportunities that come with the vast potential of China's new consumer economy and the appreciation of world-wide assets and access to quality products at a competitive price. The Company's operations are organized into segments, consisting of E-commerce services, technology Empowerment service, and Wealth Management services.

About ATNM Actinium Pharmaceuticals Inc. (Delaware)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.

Share on Social Networks: